SYRE Relative Valuation
SYRE's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, SYRE is overvalued; if below, it's undervalued.
Historical Valuation
No Data
Competitors Valuation Multiple
The average P/S ratio for SYRE's competitors is 8.74, providing a benchmark for relative valuation. Spyre Therapeutics Inc Corp (SYRE) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
People Also Watch
HROW
Harrow Inc
28.410
USD
+10.89%
DSP
Viant Technology Inc
15.390
USD
-3.99%
AOSL
Alpha and Omega Semiconductor Ltd
23.140
USD
-1.36%
SCSC
Scansource Inc
40.790
USD
+0.02%
AMRC
Ameresco Inc
14.960
USD
+1.36%
BLFS
BioLife Solutions Inc
23.590
USD
+7.28%
TBLA
Taboola.com Ltd
3.410
USD
+0.59%
MRVI
Maravai LifeSciences Holdings Inc
2.100
USD
+7.14%
FVRR
Fiverr International Ltd
32.210
USD
+1.64%
IMKTA
Ingles Markets Inc
62.820
USD
+0.90%
FAQ
Is Spyre Therapeutics Inc (SYRE) currently overvalued or undervalued?
Spyre Therapeutics Inc (SYRE) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of 164.46. The fair price of Spyre Therapeutics Inc (SYRE) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 15.18 USD , Spyre Therapeutics Inc is Undervalued By Fair .
What is Spyre Therapeutics Inc (SYRE) fair value?
How does SYRE's valuation metrics compare to the industry average?
What is the current P/B ratio for Spyre Therapeutics Inc (SYRE) as of May 19 2025?
What is the current FCF Yield for Spyre Therapeutics Inc (SYRE) as of May 19 2025?
What is the current Forward P/E ratio for Spyre Therapeutics Inc (SYRE) as of May 19 2025?